Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 08 2022 - 5:28PM
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the
discovery and development of novel antibody-based therapies, today
announced publication of four abstracts featuring preclinical data
from its expanding pipeline in advance of the AACR Annual Meeting
2022 in New Orleans, Louisiana from April 8-13, 2022. The full
abstracts are available on the AACR meeting website.
At AACR, presentations will include preclinical
results showing the potential best-in-class profiles for three
differentiated preclinical product candidates in IND-enabling
studies: ADG138, ADG206 and ADG153. The fourth presentation
introduces a new capability for the company’s proprietary
bispecific T-cell engagers (TCEs) with CD28.
Details for the poster presentations include:
- Title: ADG138, A Novel HER2×CD3 POWERbody™ Integrating
Bispecific TCE with Precision Masking to Control Cytokine Release
Syndrome and On-Target Off-Tumor Toxicity for Single Agent and
Combination Therapies in HER2-Expressing Solid TumorsDate: Tuesday
April 12, 2022Poster Session: 9:00 a.m. – 12:30 p.m. ETOnsite
Location: Exhibit Halls D-H, Poster Section 37Abstract Number:
2869
- Title: ADG206, an anti-CD137 agonistic POWERbodyTM with
tailor-made efficacy and safety profiles by strong crosslinking and
tumor selective activation for single agent and combinational
cancer immunotherapyDate: Tuesday, April 12, 2022Poster Session:
9:00 a.m. – 12:30 p.m. ETOnsite Location: Exhibit Halls D-H, Poster
Section 37Abstract Number: 2868
- Title: Tumor-targeted CD28 bispecific POWERbodyTM for safe and
synergistic T cell-mediated immunotherapyDate: Tuesday, April 12,
2022Poster Session: 9:00 a.m. – 12:30 p.m. ETOnsite Location:
Exhibit Halls D-H, Poster Section 38Abstract Number: 2888
- Title: ADG153-G1 SAFEbody, a differentiated masked anti-CD47
antibody of IgG1 subclass, demonstrates in vivo anti-tumor activity
consistent with enhanced ADCC/ADCP effects and significantly
reduced RBC-related and antigen sink liabilitiesDate: Wednesday,
April 13, 2022Poster Session: 9:00 a.m. – 12:30 p.m. ETOnsite
Location: Exhibit Halls D-H, Poster Section 39Abstract Number:
4257
“These presentations highlight the promise of our
AI-driven technology platform to build a deep, broad, and
differentiated pipeline of transformative antibody therapeutics,”
said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and
Chairman of Adagene. “Our ‘three-body’ technologies are well suited
to discover and engineer antibody-based modalities against
clinically important targets such as HER2, TROP2, B7H3, CD137, CD47
and CD28, overcoming challenges of prior platform technologies,
validated by clinical data from our ongoing clinical programs, and
endorsed by our strategic partnerships with global pharmaceutical
and biopharmaceutical companies.”
Dr. Luo continued, “We are designing safe and
effective antibody candidates across the cancer immunity cycle,
including our POWERbody approach, which integrates the SAFEbody
technology with multiple antibody-based modalities. These include
ADG138, a new HER2xCD3 bispecific TCE for solid tumors, and ADG206,
an Fc engineered anti-CD137 therapy, both designed for enhanced
safety and efficacy. Additionally, we are establishing a new
paradigm for CD28 TCEs by putting all the pieces together to ensure
ultimate safety and mitigate known risks of this target - a unique,
highly conserved epitope, our precision masking technology and a
tumor antigen targeted TCE for local activation. With these novel
therapeutic approaches, we aim to push the boundaries of what is
possible with TCEs – to achieve safe, potent and durable responses
for solid tumors.”
About Adagene Adagene Inc.
(Nasdaq: ADAG) is a platform-driven, clinical-stage
biopharmaceutical company committed to transforming the discovery
and development of novel antibody-based cancer immunotherapies.
Adagene combines computational biology and artificial intelligence
to design novel antibodies that address unmet patient needs.
Powered by its proprietary Dynamic Precision Library (DPL)
platform, composed of NEObody™, SAFEbody®, and POWERbody™
technologies, Adagene’s highly differentiated pipeline features
novel immunotherapy programs. Adagene has forged strategic
collaborations with reputable global partners that leverage its
technology in multiple approaches at the vanguard of science.
For more information, please
visit: https://investor.adagene.com. Follow Adagene on
WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark
in the United
States, China, Australia, Japan, Singapore, and
the European Union.
Safe Harbor Statement
This press release contains forward-looking
statements, including statements regarding ADG138, ADG206,
ADG153G-1 and a tumor-targeted CD28 bispecific POWERbodyTM’s
preclinical studies, the potential implications of preclinical
findings of these product candidates, and Adagene’s advancement of,
and anticipated clinical development, regulatory milestones and
commercialization of Adagene pipeline candidates. Actual results
may differ materially from those indicated in the forward-looking
statements as a result of various important factors, including but
not limited to Adagene’s ability to demonstrate the safety and
efficacy of its drug candidates; the clinical results for its drug
candidates, which may not support further development or regulatory
approval; the content and timing of decisions made by the relevant
regulatory authorities regarding regulatory approval of Adagene’s
drug candidates; Adagene’s ability to achieve commercial success
for its drug candidates, if approved; Adagene’s ability to obtain
and maintain protection of intellectual property for its technology
and drugs; Adagene’s reliance on third parties to conduct drug
development, manufacturing and other services; Adagene’s limited
operating history and Adagene’s ability to obtain additional
funding for operations and to complete the development and
commercialization of its drug candidates; Adagene’s ability to
enter into additional collaboration agreements beyond its existing
strategic partnerships or collaborations, and the impact of the
COVID-19 pandemic on Adagene’s clinical development, commercial and
other operations, as well as those risks more fully discussed in
the “Risk Factors” section in Adagene’s filings with the U.S.
Securities and Exchange Commission. All forward-looking statements
are based on information currently available to Adagene, and
Adagene undertakes no obligation to publicly update or revise any
forward looking statements, whether as a result of new information,
future events or otherwise, except as may be required by law.
Investor & Media Contact: Ami
Knoefler Adagene 650-739-9952 ir@adagene.com
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Jul 2023 to Jul 2024